Medistim (MEDI)

[Morgo26]

Has been a great run for MEDI and a lovely under the radar performer over a number of years. I bought at 40 and unfortunately sold at 70 back in 2017

[TekBot]

Presentation of second quarter and 1st half results 2020 for Medistim ASA

Sales for the quarter ended at MNOK 82.5 (MNOK 93.8), a decrease of 12.2%. Sales for the 1st half ended at MNOK 185.6 (MNOK 182.5), a 1.7 % increase. Currency neutral sales of own products was down 20.3% for the quarter, driven by the COVID-19 pandemic, particularly in the U.S. Operating result (EBIT) for the quarter ended at MNOK 27.7 (MNOK 30.9) a 10.3% decrease. Operating result for the 1st half ended at MNOK 52.5 (MNOK 50.8), an 3.3% increase. This is the best operating result for the first half ever. Medistim increased its cash position since year end with MNOK 35.8. Cash by the end of the quarter was MNOK 102.5. Payment of dividend will be evaluated at the October board meeting. So far, Medistim’s internal operations and employees have not been affected by the COVID 19. The CIDAC study was published and supports the use of Medistim’s equipment to improve outcomes during Carotid Endarterectomy procedures.
…

Vis børsmeldingen

Kilde

[TekBot]

Notification of trade in Medistim ASA

VP of Development in Medistim ASA, Erik Swensen, has sold 30.000 shares in Medstim ASA the 24th of August. The average price per share sold was NOK 235. After the sale Erik Swensen has 10.000 Medistim shares. VP of Medical in Medistim ASA, Anne Waaler, has sold 6.200 shares in Medistim ASA the 24th of August. The average price per share sold was NOK 235. After the sale Anne Waaler has 451 Medistim shares.
…

Vis børsmeldingen

Kilde

[Savepig]

Fatter ikke at kursen holder seg så godt når de bare selger og selger

[Morgo26]

Can you imagine the reaction (especially here) if this was one of Nano, PCIB, Trvx, Pho or Bgbio.

[Savepig]

[Savepig]

[TekBot]

Presentation of third quarter results 2020 for Medistim ASA

Medistim invites you to a presentation of the third quarter results for 2020 and status for the company. Because of the COVID-19 situation and the fact that Medistim has an increasing number of international investors, the third quarter results will be presented through a webinar. The webinar takes place Thursday the 22end of October and will start at 08.00 Norwegian time. The webinar will be available on Medistim website after the presentation. Representatives for the company will be: Kari Eian Krogstad - CEO Thomas Jakobsen - CFO To sign up to join the webinar please follow the link to register: https://register.gotowebinar.com/register/12885586918627085
…

Vis børsmeldingen

Kilde

[TekBot]

Medistim ASA: Resolution to distribute dividend of NOK 2.75 per share

Oslo, the 21st of October 2020. At a board meeting today, the Board of Medistim ASA (the “Company”) resolved to distribute a dividend of NOK 2.75 per share based on the Company’s net profit for the 2019 financial year. The total dividend will amount to NOK 50.1 million, which corresponds to 71% of the net profit for 2019. The Board has utilised its authorisation to resolve distribution of dividends of maximum NOK 2.75 per share, as granted by the Annual General Meeting on the 28th of April 2020. The dividend will be payable to the shareholders of the Company as of the 21st of October 2020, as registered in the Company’s shareholder register in the VPS on the 23rd of October 2020 (the record date). The shares will be traded exclusive of the right to dividends from and including the 22end of October 2020 (ex-date). The dividend will be distributed the 4th of November 2020.
…

Vis børsmeldingen

Kilde

[TekBot]

Presentation of third quarter results 2020 for Medistim ASA

Sales for the quarter ended at MNOK 83.4 (MNOK 85.5), a decrease of 2.5%. Sales as of September ended at MNOK 268.9 (MNOK 268.1). Sales in the US increased with 16.6 % in NOK. Currency neutral growth was 6.5%. Operating result (EBIT) for the quarter ended at MNOK 20.8 (MNOK 19.2) an 8.7% increase. Operating result year to date September ended at MNOK 73.3 (MNOK 70.0), a 4.8% increase. This is the best operating result for the first three quarters ever. Cashflow from operations was a solid MNOK 54.4. Cash by the end of the quarter was MNOK 114.9. The Board has decided to pay out, as previously proposed, the 2019 dividend of NOK 2.75 per share.
…

Vis børsmeldingen

Kilde

[TekBot]

Ex utbytte NOK 2,75 i dag

Aksjene i Medistim ASA noteres ex utbytte NOK 2,75 fra og med i dag, 22.10.2020.
…

Vis børsmeldingen

Kilde

[Savepig]

Voldsomt så pen bevegelse i medistim i dag, nesten så man kan lure på en fat finger noe sted?

[Savepig]

Den bevegelsen som var i Medistim for drøye to uker siden var veldig rar, og viste seg også å ikke holde.

Nede og vaker på 200 dagers snitt igjen nå

[Savepig]

MEDI: DANSKE BANK STARTER DEKNING MED KJØPSANBEFALING, KURSMÅL 270

Oslo (TDN Direkt): Danske Bank Markets tar opp dekning på Medistim med et tolv-måneders kursmål på 270 kroner og en kjøpsanbefaling på aksjen.

Det kommer frem av analyse fra meglerhuset torsdag.

Danske Bank argumenterer for at selskapet er i god posisjon for å fortsette penetrasjon av, og ekspandere i, det de beskriver som et 4 milliarder kroners marked innen hjerte- og karkirurgi.

Ifølge analysen er Medistim den eneste leverandøren i markedet som kombinerer “transit time flow measurement” (TTFM) og “high frequency ultrasound” (HFUS), noe som gjør at meglerhuset tror selskapet vil fortsette å vokse mer enn konkurrentene.

Lars Henrik Bjerke [email protected] Infront TDN Direkt

[Savepig]

Foruroligende tall inne på nordnet i dag!

[TekBot]

Medistim partners with LivaNova as their new distributor for India

(Oslo, 5th of January 2021) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that they have signed a Distributor Agreement with LivaNova for distribution of Medistim products in India.

With its population size of about 1,4 billion, India is a large and emerging market for Medistim’s ultrasound devices. Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size of about half of the USA. The disproportionally low number of procedures compared to population size, as well as the growth in the general economy and health care investments, are expected to drive higher growth in CABG procedures in this market compared to the developed, western world. Hence, India is an important market for Medistim’s long term strategy and growth.
…

Vis børsmeldingen

As the cost of a CABG procedure in India is significantly lower than in many other markets , Medistim has a 2-tier product strategy in this market, offering both a lower-priced entry-level flowmeter (SonoQ), as well as the high-end portfolio with high frequency ultrasound imaging (HFUS) as an additional option (MiraQ).
As of January 1st 2021, LivaNova will represent Medistim in India, through its Cardiovascular business unit. LivaNova is a globally operating medical device manufacturer with a strong foothold in cardiac surgery. They are a market leader within heart-lung machines, hence targeting the same target customers as Medistim’s intraoperative ultrasound devices.

“LivaNova has already proven to be a strong partner for us in Australia, and we are very excited to develop the business in India together as well,” said Medistim President and CEO, Kari E. Krogstad. “With their highly competent local team and strong product synergies we should be perfectly positioned to build a strong business over the years to come.”

“We are pleased to be expanding our partnership with Medistim to now include distribution in India” said Sujay Mashru, Vice President and Managing Director - Asia Pacific of LivaNova. “This unique portfolio of products for surgical guidance and blood flow measurement will strengthen our Cardiovascular business in India and enable us to leverage our strong expertise in cardiac surgery to grow the market”.

About LivaNova:
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]

Kilde

[Savepig]

Bittelitt skuffet over at den ikke klarte 260 i denne omgang, men ser helt ok ut om man zoomer ut

[TekBot]

Transfer of shares to CEO

Medistim ASA has transferred 12,500 shares to Medistim CEO Kari Krogstad. It is part of her agreement with the Board of Medistim that she receives 12,500 shares. The agreement has been previously described in the Company’s Annual Report. Medistims last traded share price in 2020 was 250.00 so the shares are transferred at this cost. Medistim ASA has 136,500 own shares and after the transfer to Kari Krogstad the company has 124,000 own shares shares. Kari Krogstad has after the latest transfer 91,802 shares in Medistim ASA.
…

Vis børsmeldingen

Kilde

[TekBot]

Major shareholder announcement for MediStim ASA

•Identity of the issuer: Medistim ASA (ISIN NO0010159684)
•Tradedate: 04. February 2021
•Shareholder: Universal-Investment-Gesellschaft mbH, Germany
…

Vis børsmeldingen

•Shares: 929,161 (indirect Art 10 of Directive 2004/109/EC) (DTR5.2.1))
•Voting rights: 5.07% (indirect Art 10 of Directive 2004/109/EC) (DTR5.2.1))
•Reason for the notification: An acquisition of voting rights
•The chain of controlled companies through which the shares or rights are owned:
Universal-Investment-Gesellschaft mbH
Universal-Investment-Luxembourg S.A.

Frankfurt am Main, 08. February 2021

Kilde

[Savepig]

Medistim klokker inn ATH ubesværet og greit etter ny eier flagger 5%

Medistim $MEDI clocking in ATH for OSL:MEDI by savepiginvest

8.2.2021, 14:46 · TDN Finans Delayed
MEDI: UNIVERSAL-INVESTMENT FLAGGER OVER 5 PROSENT EIERANDEL
Oslo (TDN Direkt): Universal-Investment GmbH flagger en eierandel på 5,07 prosent i Medistim.Det fremgår av en melding mandag.